Big Pharma’s Anti-Competitive Tactics Are The Root Cause of Out-of-Control Prescription Drug Prices BIG PHARMA’S PATENT ABUSE IS THE ROOT CAUSE OF OUT-OF-CONTROL PRESCRIPTION DRUG PRICES Big Pharma has a long history of price-gouging American patients through tactics designed to game the U.S. patent system and block competition from more affordable alternatives — enabling Big Pharma to maintain […]
I-MAK Analysis Reveals Patent Abuse on Four Blockbuster Medications Generated $158 Billion for Big Pharma On Tuesday, the Initiative for Medicines, Access, and Knowledge (I-MAK) released a new study detailing the massive financial implications of Big Pharma’s egregious patent thickets meant to block competition from more affordable alternatives to blockbuster brand name prescription drugs. The […]
A History of Big Pharma’s Egregious Pricing Practices and Billions of Dollars in Spending on Direct-to-Consumer Advertising The U.S. Department of Health and Human Services (HHS) announced the first 10 drugs eligible for negotiation in the Medicare Part D program. The drugs are all prolific earners for the Big Pharma companies that market them. Since […]
Brand Name Drug Companies Claim Lowering Rx Prices Will Undercut R&D — The Facts Disagree For far too long Big Pharma has used the excuse that research and development (R&D) costs justify out-of-control prescription drug prices and that solutions to lower prices threaten innovation into new breakthroughs. These tired arguments, which Big Pharma wields like […]
AARP Analysis Finds Prices for Best-Selling Medicare Part D Drugs Rose 226 Percent Each on Average Due to Big Pharma’s Price Hikes Last week, AARP’s Public Policy Institute released a new analysis which found that list prices for the top 25 best-selling prescription medications in the Medicare Part D Program have increased 226 percent on […]
Big Pharma Giants Once Again Top Wall Street Expectations in Final Round of Second Quarter Earnings Reports While Continuing to Price-Gouge American Patients Rounding out Big Pharma’s earnings calls for the second quarter, brand name drug makers Sanofi, AstraZeneca, Amgen and Eli Lilly all once again demonstrated that Big Pharma continues to surpass Wall Street […]
International Experts Slam Big Pharma’s Egregious Offshoring Scam of U.S. Taxpayers Last week, Business Insider published an article examining the pharmaceutical industry’s “offshoring” of U.S. profits to avoid paying taxes in the U.S. The article, titled ‘Big Pharma’s Big Tax Dodge,” was written by Brad Setser and Tess Turner, of The Council on Foreign Relations […]
More Q2 2023 Earnings Reports Demonstrate Big Pharma Firms Top Wall Street Expectations After Hiking Prices Another round of second-quarter earnings reports from Big Pharma giants Pfizer and Merck sees the pharmaceutical industry once again beating Wall Street expectations after hiking prices on blockbuster products. Pfizer and Merck both reported Q2 earnings that topped Wall […]
Big Pharma Giants Boast Better Than Expected Q2 Earnings While Price-Gouging Patients Another round of second-quarter earnings reports from GlaxoSmithKline and AbbVie showcased once again that hiking prices on brand name prescription drugs continues to fuel big profits for the pharmaceutical industry. Both Big Pharma companies topped Wall Street analysts’ earnings expectations for the second […]
Top Five Drug Makers By U.S. Market Cap Plowed Soaring Earnings Into Stock Buybacks and Dividends Rather Than R&D In case you missed it, on Monday, a new analysis from Accountable.US found the five largest pharmaceutical companies in the U.S. by market cap – Eli Lilly, Johnson & Johnson, Merck, AbbVie and Pfizer – had total earnings […]